NEW YORK — French biosensor developer Grapheal said on Tuesday that it has raised €1.9 million ($2.3 million) that it will use in part to support the development of a saliva-based SARS-CoV-2 antigen test.
The funding includes seed money from Novalis Biotech's Acceleration Fund, grants, and convertible notes and loans from French investment bank Bpifrance.